Replies to post #15598 on Momenta Pharmaceuticals, Inc. (MNTA)

[imnot6]

For Ref: bstract is here as part of 2016 ASCO submissions
http://abstracts.asco.org/176/AbstView_176_167912.html

[DewDiligence]

MNTA presents final Necuparanib data from phase-1 portion of phase-1/2 trial in pancreatic cancer at ASCO:

#msg-123093925

The PR rate of 56% (9/16) is higher than the 50% rate in the ASCO abstract; i.e. one additional patient had a response after the cut-off date for the abstract.